Regeneron Pharmaceuticals, Inc.
COMBINATION THERAPY TO TREAT BRAIN CANCER

Abstract:

Provided herein are nucleic acid molecules, proteins, compositions and methods for treating brain cancer in a subject. In some embodiments, the compositions comprise cancer antigens hTERT, WT-1, and PSMA. In some embodiments, the compositions also comprise an adjuvant. The methods comprise administering to a subject in need thereof the cancer antigens. According to certain embodiments, the methods further involve administering the adjuvant and an anti-PD-1 antibody. In certain embodiments, the methods further comprise administering radiation therapy and/or a chemotherapeutic agent. In certain embodiments, the methods are clinically proven safe, clinically proven effective, or both.